Cargando…

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore

BACKGROUND: CDK4/6 inhibitors have shown promising results for treating advanced breast cancer (ABC) and are routinely used in Singapore. In view of their high costs, it is important to assess their relative value compared to existing standards of care in the local setting. AIMS: This study evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loke, Lydia, Lee, Soo‐Chin, Pearce, Fiona, Ng, Kwong, Aziz, Mohamed Ismail Abdul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941436/ https://www.ncbi.nlm.nih.gov/pubmed/33085843 http://dx.doi.org/10.1002/cnr2.1308

Ejemplares similares

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
por: Tan, Ping-Tee, et al.
Publicado: (2018)

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
por: Phua, Lee Cheng, et al.
Publicado: (2020)

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore
por: Cheng, Li-Jen, et al.
Publicado: (2021)

Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
por: Al-Ziftawi, Nour Hisham, et al.
Publicado: (2022)

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
por: Bardia, Aditya, et al.
Publicado: (2021)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017)

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
por: Berrios, Kevin, et al.
Publicado: (2022)

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
por: Alotaibi, Wedad H., et al.
Publicado: (2022)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2017)

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
por: Harbeck, Nadia, et al.
Publicado: (2020)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
por: Buehler, Anna Maria, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Direct Medical Cost of Type 2 Diabetes in Singapore
por: Shuyu Ng, Charmaine, et al.
Publicado: (2015)

Cost-effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore
por: Cheng, Li-Jen, et al.
Publicado: (2019)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Diagnostic challenge for ovarian malignant melanoma in premenopausal women: Primary or metastatic?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Singapore
por: Wee Loon, Ng-Loy
Publicado: (2008)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Ribociclib in newly diagnosed hepatitis B infection: A case report
por: Di Costanzo, Fabrizio, et al.
Publicado: (2023)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

Premenopausal osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2013)

Biomarkers of mammographic density in premenopausal women
por: His, Mathilde, et al.
Publicado: (2021)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

The burden of costs on health services by patients with neuro‐ischaemic ulcers in Singapore
por: Nazeha, Nuraini, et al.
Publicado: (2022)

Prevalence of propolis allergy in Singapore
por: Kwong, Hui Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tfci5hodip3llhijs4ob88fp5e